So what are the five molecules waiting in the wings to go forward into clinical trials
Starpharma over the years have been working on several molecules. Most probably due to money constraints and a small team, it needed to focus on those that were commercially very attractive
As we all know in recent times........those in current preclinical/clinical trials include Dep Docetaxel (P2), Dep Carbazitaxel (P1), and Dep Irinotecan (PC and going into P1)
However there was a molecule Dep Oxaliplatin that was in advanced preclinical trials a few years back. Maybe this will be one going forward
Other drugs under study were Carboplatin, Gemcitabine, Methotrexate, Paclitaxel, and Doxorubican.
Starpharma were also working on hormones - Insulin (partnered program) and Testosterone
Starpharma has a collaboration with leading undisclosed big pharma's who specialise in Antibody Drug Conjugates. In February 2016 it had completed preclinical studies on HER2-targeted DEP™ conjugate
For your information Antibody Drug Conjugates belong to a class called Biologics. An example of this is Roche's Herceptin and Kadcyla. And guess what???
Herceptin patent expires is 2019!!!
Kadcyla patent expires in 2026
The sales of Herceptin 2017.........US$7 billion.
The sales of Kadcyla in 2017......US$914 million.
Yes that's right........and Starpharma has an improved version of both of these drugs (HER2-targeted DEP™ conjugate)
It is interesting to note that the timing for the undisclosed partners in reference to ADC's was initiated two months after the results were announced
Co-incidence.....I don't think so
So there is no doubt in my mind Roche is one of these undisclosed partners involved in ADC's. It is obvious
And now let us look at Conjuncivitis........Again the preclinical (partnered or internal......not too sure) must surely be completed....or close to it. There were some large pharma's having a sniff, as has been indicated by Starpharma.
Also note drug delivery in ocular use with dendrimers has plenty of advantages.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)